Nuvilex Announces Preliminary Data From Preclinical Study

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nuvilex Announces Preliminary Data From Preclinical Study of Effects of Its Pancreatic Cancer Treatment on Ascites Fluid Formation

SILVER SPRING, Md., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex's pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.

Preliminary data analysis suggests that treatment with Nuvilex's live-cell encapsulation technology, Cell-in-a-Box ® plus ifosfamide, produces a significant survival advantage as compared to non-treated control animals. Nuvilex's treatment appears to be at least as good as cisplatin, the current standard of care for ovarian cancer. However, when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin, the survival rate was greatly enhanced. The final data analysis will be released in the future.

"The data itself is not only exciting from an ascites point of view, but also provides further evidence that encapsulated cells plus ifosfamide are effective at treating yet another type of malignant tumor. This provides the rationale for additional clinical trials of this novel therapy," said Prof. Dr. Walter H. Günzburg, the Chief Scientific Officer of Nuvilex.

Nuvilex CEO and President, Kenneth L. Waggoner, stated, "We couldn't be more elated with the information we're receiving from TD-2 as Nuvilex's preclinical studies progress. Based on the preliminary data we've received, Nuvilex's treatment appears to be performing admirably alone and remarkably as a combination treatment. This data justifies our decision last year to purchase the exclusive global rights to further develop Cell-in-a-Box ® cancer treatments."

About Nuvilex

Nuvilex (OTCQB:NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box ® . This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. Nuvilex is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. In addition, Nuvilex is developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids. Nuvilex is examining ways to exploit the benefits of Cell-in-a-Box ® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Nuvilex a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.

Safe Harbor

This press release may contain forward-looking statements regarding Nuvilex and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to Nuvilex or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of Nuvilex, that could cause actual results to differ materially from those set forth in the forward-looking statements include Nuvilex's ability to continue as a going concern, delays or unsuccessful results in clinical trials or flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of Nuvilex's intellectual property and Nuvilex's continued ability to raise capital. Nuvilex does not assume any obligation to update any of these forward-looking statements.

More information about Nuvilex can be found at www.nuvilex.com . It can also be obtained by contacting Investor Relations.

Investor Relations Contacts: Clare Matschullat Blueprint Life Science Group Telephone: 415.375.3340 Ext. 106

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 27

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 95

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 196

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 118

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 51

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Science Applications Intl's Earnings Preview: Key Insights Ahead

Updated Category News Views 170

Understanding Science Applications Intl's Earnings Preview Science Applications Intl (NYSE: SAIC) is gearing up for its quarterly earnings announcement. Investors are eager to see how the company performs and whether it meets analysts' expectations. What to Anticipate Analysts project Science Applications Intl will report an earnings per share (EPS) of $2.11, which could...

Continue Reading
Innovative Aerogels Paving the Path for Water Harvesting Solutions

Updated Category News Views 285

Introduction to Atmospheric Water Harvesting The world faces an alarming freshwater crisis, with projections indicating that vast segments of the population are at risk of water scarcity. In response, researchers have innovatively turned to atmospheric water harvesting, particularly highlighting the advancements made by the National University of Singapore (NUS). They...

Continue Reading
Class Action Lawsuit Alert for Tronox Holdings Plc Investors

Updated Category News Views 131

Insights into the Tronox Holdings Class Action Lawsuit Investors in Tronox Holdings Plc (NYSE: TROX) should be aware of a class action lawsuit initiated against the company. This legal action centers around allegations of potential securities fraud and improper business practices by Tronox and some of its leadership. The firm Pomerantz LLP, known for its expertise in...

Continue Reading
Rapport Therapeutics Set to Showcase Innovations in Healthcare

Updated Category News Views 128

Rapport Therapeutics to Attend Major Investor Conferences BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology firm at the forefront of developing small molecule precision medicines targeting neurological and psychiatric disorders, has expressed its excitement about participating in two notable investor conferences soon. Details of Upcoming...

Continue Reading
Northwestern Mutual Achieves Unmatched Financial Strength Ratings

Updated Category News Views 353

Northwestern Mutual Achieves Elite Financial Ratings for 35 Years For an impressive 35 years, Northwestern Mutual has consistently earned top financial strength ratings from the nation's leading rating agencies. This recognition underscores the company’s commitment to maintaining a robust financial foundation, which plays a crucial role in their ability to serve clients...

Continue Reading